Scarica l'app Stockscreener
1.00
6.54%
-0.07
Dopo l'orario di chiusura:
1.03
0.03
+3.00%
Precedente Chiudi:
$1.07
Aprire:
$1.1
Volume 24 ore:
355.56K
Relative Volume:
0.37
Capitalizzazione di mercato:
$133.24M
Reddito:
-
Utile/perdita netta:
$-18.86M
Rapporto P/E:
-0.0623
EPS:
-16.054
Flusso di cassa netto:
$-17.68M
1 W Prestazione:
-15.97%
1M Prestazione:
-60.47%
6M Prestazione:
-44.75%
1 anno Prestazione:
-85.95%
Intervallo 1D:
$0.9801
$1.24
Intervallo di 1 settimana:
$0.9801
$1.295
Portata 52W:
$0.92
$8.57
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Nome
Indaptus Therapeutics Inc
Settore
Industria
Telefono
(646) 427-2727
Indirizzo
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
1.00 | 142.57M | 0 | -18.86M | -17.68M | -16.05 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Indaptus Therapeutics Inc Borsa (INDP) Ultime notizie
Indaptus Therapeutics Stock Price Forecast. Should You Buy INDP? - StockInvest.us
Indaptus Therapeutics Inc (NASDAQ: INDP) Share Price, INDP Stock News, INDP Share Price & Updates - Kalkine
Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Declines By 64.1% - MarketBeat
Indaptus Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Indaptus Therapeutics Q2 EPS beats estimate as loss narrows - scanx.trade
Indaptus Therapeutics Reports Q2 Results Amid Strategic Pivot - tipranks.com
Indaptus Therapeutics, Inc. 2Q 2026: Net loss $(1.79M), EPS $(0.02) — 10-Q Summary - TradingView
Indaptus Therapeutics (Nasdaq: INDP) cuts losses and raises $12M in Q2 - Stock Titan
Indaptus Q2 Net Loss Narrows to $1.8 Million - Quiver Quantitative
Indaptus Therapeutics (INDP) slashes R&D costs and bolsters cash after $12M raise - Stock Titan
Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - marketscreener.com
Indaptus Therapeutics Inc (INDP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Indaptus Therapeutics (INDP) to Announce Earnings on Monday - MarketBeat
Qinglai Lu Net Worth (2026) - GuruFocus
Indaptus Therapeutics Inc (INDP) Stock News Today - TradingKey
Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Up 88.8% in July - MarketBeat
Indaptus Therapeutics Inc (INDP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
INDP|Indaptus Therapeutics Inc|Price:2.610|Chg%:-0.160 - TradingKey
Indaptus Therapeutics Inc (INDP) Balance Sheet - TradingKey
INDP|Indaptus Therapeutics Inc|Price:2.100|Chg%:+0.060 - TradingKey
Indaptus Therapeutics Inc (INDP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Indaptus Therapeutics Inc (INDP) Cash Flow - TradingKey
Indaptus Therapeutics Market Sentiment - Benzinga España
Indaptus Therapeutics Inc (INDP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Indaptus Therapeutics Inc (INDP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
INDP|Indaptus Therapeutics Inc|Price:2.060|Chg%:-0.550 - TradingKey
Indaptus Therapeutics, Inc. Revenue Breakdown – NASDAQ:INDP - TradingView
Indaptus Therapeutics Inc (INDP) Institutional Confidence - TradingKey
TradingKey - TradingKey
Indaptus Therapeutics Inc (INDP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Indaptus Therapeutics (INDP) Q3 2025 earnings summary - Quartr
Signal Proxy Intelligence Recommends Full Support for All Three Items at Indaptus Therapeutics, Inc. Annual Meeting - Nonstop Local News
Indaptus Therapeutics, Inc. SEC Filing (Jul 20, 2026) - Stock Titan
Indaptus Therapeutics (NASDAQ: INDP) seeks approval for 2026 equity plan - Stock Titan
INDP Q4 2025 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Navigates Clinical DevelopmentQuarterly Financial Update - po-news-eg.net
Insider Traders Lose US$34k As Indaptus Therapeutics Drops - simplywall.st
INDP Q4 2025 Earnings: Wider-than-Expected Loss as Stock Declines Nearly 6%Revenue Estimate Trend - dars.gov.et
Indaptus Therapeutics Company Profile & Introduction - Moomoo
INDP Q4 2025 Earnings: EPS Misses Expectations Amid Zero Revenue; Stock Declines 1.96%Cost Structure Review - po-news-eg.net
Indaptus Therapeutics (INDP) News Flow - Moomoo
INDP Q4 2025 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEarnings Surprise Score - dars.gov.et
Form 13D/A Indaptus Therapeutics For: 26 June By Investing.com - Investing.com Australia
Sino Lion Ventures (INDP) files amended 13D on 38,895,000 shares - Stock Titan
Indaptus Therapeutics (INDP) CEO details 8.44% common stock stake - Stock Titan
Indaptus (INDP) investor Ting Yang stake falls to 8.44% after share issuance - Stock Titan
Form S-3 Indaptus Therapeutics Inc For: 26 June By Investing.com - Investing.com South Africa
Indaptus Therapeutics (INDP) registers 18.864M shares; clinical program paused - Stock Titan
Revenue per share of Indaptus Therapeutics, Inc. – NASDAQ:INDP - TradingView
Indaptus Therapeutics Announces Private Placement of Common Stock - The Globe and Mail
INDAPTUS THERAPEUTICSTO ISSUE 20 MLN SHARES AT $0.6 PER SHARESEC FILING - Moomoo
Indaptus TherapeuticsTo Issue 20 Million Shares At $0.6 Per ShareSEC Filing - TradingView
Indaptus Therapeutics Inc Azioni (INDP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):